1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Specifications of predominant nonserious adverse effects 4 weeks after intrathecal gadobutrol in various doses^{^a}
iNPH Cohort Non-iNPH Cohort
0.50 mmol (n = 20) 0.25 mmol (n = 86) 0.10 mmol (n = 28) 0.50 mmol (n = 34) 0.25 mmol (n = 15)
No adverse events (No.) (%) 19 (95.0%) 82 (95.3%) 27 (96.4%) 33 (97.1%) 13 (86.7%)
Adverse events present (No.) (%) 1 (5.0%) 4 (4.7%) 1 (3.6%) 1 (2.9%) 2 (13.3%)
Predominant adverse events 
 Mild headache, nausea, and/or dizziness (No.) (%) 1 (5.0%) 2 (2.3%) 1 (3.6%) 0 1 (6.7%)
 Moderate headache, nausea, and/or dizziness (No.) (%) 0 2 (2.3%) 0 0 0
 Severe headache, nausea, and/or dizziness (No.) (%) 0 0 0 0 0
 Back pain from spinal puncture (No.) (%) 0 0 0 0 1 (6.7%)
 Other (No.) (%) 0 0 0 1 (2.9%) 0
↵a Data are given as numbers (percentages are in parentheses). The Pearson χ² test showed no statistical differences between groups.